Clinical Trials
17 trialsNCT03816163 2026-06-04
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT06511726 2026-06-04
CATPCC-01
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT04753879 2026-06-03
Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT07076121 2026-06-03
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Bristol-Myers Squibb
Phase 2/3 Active not recruiting
NCT04104672 2026-06-02
ARC-8
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT06018337 2026-06-02
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
DualityBio Inc.
Phase 3 Active not recruiting
NCT06608927 2026-06-02
PRISM-1
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT06625320 2026-06-02
RASolute 302
Revolution Medicines, Inc.
Phase 3 Active not recruiting
NCT04594772 2026-06-01
Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
University of Cincinnati
Phase 2 Active not recruiting
NCT05633667 2026-06-01
VELOCITY-Lung
Gilead Sciences
Phase 2 Active not recruiting
NCT06360354 2026-06-01
MTAPESTRY 103
Amgen
Phase 1 Active not recruiting
NCT04310007 2026-05-29
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04015778 2026-05-20
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
Guangdong Association of Clinical Trials
Phase 2 Active not recruiting
NCT03530397 2026-05-19
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
MedImmune LLC
Phase 1 Active not recruiting
NCT07280377 2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2 Active not recruiting
NCT05374512 2026-05-15
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
Phase 3 Active not recruiting
NCT03819465 2026-05-12
MAGELLAN
AstraZeneca
Phase 1 Active not recruiting